Glenn Sblendorio, M.B.A., is Chief Executive Officer and President of Ophthotech Corporation. He joined Ophthotech in 2016 as Executive Vice President, Chief Operating Officer and Chief Financial Officer and was appointed President in January 2017 while continuing to serve as Chief Financial Officer. He ceased being CFO in April 2017. Mr. Sblendorio served as a member of the Board of Directors of Ophthotech from 2013 to 2016 and rejoined the Board in May 2017. Prior to joining Ophthotech, he served as President and Chief Financial Officer and member of the Board of Directors of The Medicines Company from 2006 to 2016. Mr. Sblendorio served as Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. from 2002 through 2005 when it was sold to OSI Pharmaceuticals. From 2000 through 2002, he held the title of Senior Vice President of Business Development for The Medicines Company. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc. in a variety of senior financial positions. Mr. Sblendorio currently serves on the Board of Directors of Amicus Therapeutics and Intercept Pharmaceuticals. Mr. Sblendorio received his BA from Pace University and an MBA from Fairleigh Dickinson University and is a graduate of the Harvard Business School Advanced Management Program.